Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Speedel (SWX:SPPN) said it will focus its pipeline on avosentan (SPP301) for diabetic nephropathy and its next-generation renin inhibitors and will
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury